Lampros Fotis

Prof. Lampros Fotis

Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Attikí, Greece
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2016 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
LFLampros Fotis
Lampros Fotis
PTPaul V. Tuttle
Paul V. Tuttle
KBKevin W. Baszis
Kevin W. Baszis
PPPeri H. Pepmueller
Peri H. Pepmueller
TMTerry L. Moore
Terry L. Moore
AWAndrew J White
Andrew J White
A small percentage of children with Henoch-Schönlein purpura (HSP) develop a chronic form of the disease that often requires prolonged corticosteroid therapy. Disease modifying anti-rheumatic agents (DMARDs) or biologics have been successfully used to treat those refractory cases. Azathioprine is a DMARD that has been reported to be effective in HSP nephritis and in adult cutaneous leukocytoclastic vasculitis, a condition with cutaneous histology similar to HSP. A description of 6 cases with relapsing HSP without significant renal involvement, treated with azathioprine are reported. All 6 cases met the classification criteria for the diagnosis of HSP, had relapsing symptoms despite corticosteroid use, were successfully treated with azathioprine and were tapered off of corticosteroids. The duration of azathioprine therapy ranged from 7–21 months and no adverse events were reported. Azathioprine is effective in controlling prolonged relapsing symptoms of HSP, allowing earlier discontinuation of corticosteroids. This report shows that azathioprine can be included in the therapeutic options for relapsing HSP and is the first case series in the literature of azathioprine use in HSP without significant renal involvement.

17 April 2021 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
Sophie I. MavrogeniSophie I. Mavrogeni
Sophie I. Mavrogeni
GKGenovefa D Kolovou
Genovefa D Kolovou
VTVasileios Tsirimpis
Vasileios Tsirimpis
DKDimitrios Kafetzis
Dimitrios Kafetzis
GTGeorgios Tsolas
Georgios Tsolas
LFLampros Fotis
Lampros Fotis

14 August 2022 in Cureus
Verified
Journal Article
Open access
Irene LidorikiIrene Lidoriki
Irene Lidoriki
GSGeorge Stavrou
George Stavrou
DIMITRIOS SCHIZASDIMITRIOS SCHIZAS
DIMITRIOS SCHIZAS
Maximos FrountzasMaximos Frountzas
Maximos Frountzas
LFLampros Fotis
Lampros Fotis
Katerina KotzampassiKaterina Kotzampassi
Katerina Kotzampassi
Background: Patients suffering from thalassemia have decreased levels of lean body mass and an increased nutritional risk. To assess the body composition and vitamin D levels of thalassemic patients in relation to nutritional risk. Methods: A total of 67 consecutive adult patients who were diagnosed with thalassemia major and followed a regular blood transfusion scheme were included in this study. Demographic and clinical data were collected for each participant. Blood samples were collected to assess 25-hydroxy-vitamin D (25-OH-D) levels. The assessment of patients’ nutritional risk was based on the Malnutrition Universal Screening Tool. Body composition assessment was based on bioelectrical impedance analysis (BIA). Results: Eleven patients (16.4%) and five patients (7.5%) were at moderate and high risk for malnutrition, respectively. Moreover, 86.6% of patients had a low fat-free mass index (FFMI) and 74.6% of patients had a high-fat mass (FM) index. The prevalence of sarcopenic obesity and 25-OH-D deficiency was 64.2% and 92.2%, respectively. Medium and high-risk patients had significantly lower BMI (18.81 ± 1.29 vs 23.90 ± 2.65 kg/m2, p<0.001), lower FFM index (12.80 ± 1.38 vs 14.19 ± 1.89 kg/m2, p=0.009) and lower FM index (5.97 ± 1.86 vs 9.70 ± 2.70 kg/m2, p<0.001) than their low-risk counterparts. Conclusions: Adult patients with β-thalassemia major had low levels of vitamin D and altered body composition, presenting with increased adiposity, low levels of lean body mass, and high rates of sarcopenic obesity. Timely detection of patients at risk could lead to the prioritization of patients who could benefit from nutritional interventions.

17 February 2015 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
LFLampros Fotis
Lampros Fotis
KBKevin W. Baszis
Kevin W. Baszis
AFAnthony R. French
Anthony R. French
MCMegan A. Cooper
Megan A. Cooper
AWAndrew J. White
Andrew J. White

25 June 2025 in Life
Verified
Journal Article
Open access
PDF file
AAAikaterini Agrafiotou
Aikaterini Agrafiotou
ESEvdoxia Sapountzi
Evdoxia Sapountzi
Angeliki MargoniAngeliki Margoni
Angeliki Margoni
LFLampros Fotis
Lampros Fotis
Kawasaki disease (KD) is a systematic inflammatory condition that results in vasculitis and possible progression to the development of coronary artery lesions if left untreated. Disease pathogenesis is not fully understood, and diagnosis is based on clinical symptoms, with limited reliability considering that KD progression is time sensitive. This is further complicated by the shared clinical characteristics with other febrile diseases. Early diagnosis and prompt treatment start are associated with good prognosis in most patients. However, up to 20% of patients are resistant to available therapeutic agents and would benefit from alternative regimens. Therefore, identification of biomarkers that can provide insights on disease pathogenesis are necessary to enable early diagnosis and initiation of treatment, as well as to predict treatment responses. To this end, immunophenotyping, most commonly by flow cytometry, has been crucial in identifying central factors in KD pathogenesis. The available literature on such factors is vast and may include contradictory findings. Therefore, we aimed to summarize the available literature of the last decade on the immunophenotype of KD, focusing on biomarkers associated with disease pathogenesis and those associated with treatment response. Our review highlights the role of cells of both the innate and adaptive immune system in disease pathogenesis, as well as the role of various secreted and cell surface proteins, including inflammatory cytokines, chemokines, complement receptors, and chemoattractants both in KD pathogenesis and in treatment response.

21 April 2022 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
DNDionysis Nikolopoulos
Dionysis Nikolopoulos
LFLampros Fotis
Lampros Fotis
OGOurania Gioti
Ourania Gioti
AFAntonis Fanouriakis
Antonis Fanouriakis